Fluphenazine Decanoate

Chorea, Depression, Sedation + 4 more
Treatment
1 FDA approval
20 Active Studies for Fluphenazine Decanoate

What is Fluphenazine Decanoate

FluphenazineThe Generic name of this drug
Treatment SummaryThorazine is a psychiatric medication used for treating psychosis. It works in a similar way to chlorpromazine and is used to control symptoms including hallucinations and delusions.
Fluphenazine Hydrochlorideis the brand name
image of different drug pills on a surface
Fluphenazine Decanoate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Fluphenazine Hydrochloride
Fluphenazine
1987
181

Approved as Treatment by the FDA

Fluphenazine, also known as Fluphenazine Hydrochloride, is approved by the FDA for 1 uses including Schizophrenia .
Schizophrenia
Helps manage Psychosis

Effectiveness

How Fluphenazine Decanoate Affects PatientsFluphenazine is a drug used to treat schizophrenia and other mental illnesses. It has not been proven to help with behavior issues in people with intellectual disabilities.
How Fluphenazine Decanoate works in the bodyFluphenazine affects dopamine receptors in the brain to reduce the production of hormones from the hypothalamus and pituitary gland. This can lead to changes in metabolism, body temperature, alertness, blood pressure, and vomiting.

When to interrupt dosage

The amount of Fluphenazine Decanoate is conditioned by the determined condition, for instance Schizophrenia, Gilles de la Tourette's Syndrome and Sedation therapy. The dosage fluctuates in accordance with the method of administration (e.g. Tablet, film coated - Oral or Intramuscular) specified in the following table.
Condition
Dosage
Administration
Depression
, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL
, Oral, Solution, concentrate, Solution, concentrate - Oral, Elixir, Elixir - Oral, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet, Tablet - Oral, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous
Schizophrenia
, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL
, Oral, Solution, concentrate, Solution, concentrate - Oral, Elixir, Elixir - Oral, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet, Tablet - Oral, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous
Sedation therapy
, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL
, Oral, Solution, concentrate, Solution, concentrate - Oral, Elixir, Elixir - Oral, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet, Tablet - Oral, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous
Tourette Syndrome
, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL
, Oral, Solution, concentrate, Solution, concentrate - Oral, Elixir, Elixir - Oral, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet, Tablet - Oral, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous
Chorea
, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL
, Oral, Solution, concentrate, Solution, concentrate - Oral, Elixir, Elixir - Oral, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet, Tablet - Oral, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous
Sedation
, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL
, Oral, Solution, concentrate, Solution, concentrate - Oral, Elixir, Elixir - Oral, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet, Tablet - Oral, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous
Huntington Disease
, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL
, Oral, Solution, concentrate, Solution, concentrate - Oral, Elixir, Elixir - Oral, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet, Tablet - Oral, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous

Warnings

Fluphenazine Decanoate has seven contraindications, so it should not be taken when experiencing the conditions outlined in the following table.Fluphenazine Decanoate Contraindications
Condition
Risk Level
Notes
Brain Injuries
Do Not Combine
Disease
Do Not Combine
Liver Damage
Do Not Combine
Mental Depression
Do Not Combine
Hypnotics
Do Not Combine
Brain Injuries
Do Not Combine
Coma
Do Not Combine
There are 20 known major drug interactions with Fluphenazine Decanoate.
Common Fluphenazine Decanoate Drug Interactions
Drug Name
Risk Level
Description
Amisulpride
Major
Fluphenazine may increase the antipsychotic activities of Amisulpride.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Fluphenazine.
Azelastine
Major
Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Dacomitinib
Major
The metabolism of Dacomitinib can be decreased when combined with Fluphenazine.
Deutetrabenazine
Major
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Deutetrabenazine.
image of a doctor in a lab doing drug, clinical research

Fluphenazine Decanoate Novel Uses: Which Conditions Have a Clinical Trial Featuring Fluphenazine Decanoate?

640 active investigations are examining the potential of Fluphenazine Decanoate to alleviate Huntington Disease, Sedation therapy and Choreiform movements.
Condition
Clinical Trials
Trial Phases
Sedation therapy
0 Actively Recruiting
Sedation
2 Actively Recruiting
Early Phase 1, Not Applicable
Tourette Syndrome
0 Actively Recruiting
Depression
302 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3
Huntington Disease
5 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Chorea
0 Actively Recruiting
Schizophrenia
32 Actively Recruiting
Early Phase 1, Not Applicable, Phase 4

Fluphenazine Decanoate Reviews: What are patients saying about Fluphenazine Decanoate?

5Patient Review
7/2/2015
Fluphenazine Decanoate for Schizophrenia
I was on other medication for three years without any success, so you can imagine my relief when this drug actually worked. The voices I had been hearing were gone overnight.
4.3Patient Review
9/26/2009
Fluphenazine Decanoate for Schizophrenia
This treatment was effective and I'm now back to feeling normal. Thank you!
4Patient Review
3/7/2008
Fluphenazine Decanoate for Mental Disorder with Loss of Normal Personality & Reality
3.7Patient Review
8/21/2011
Fluphenazine Decanoate for Mental Disorder with Loss of Normal Personality & Reality
This medication has been used to treat elderly patients for many years. Some oral movements are controlled with other meds; however, the patient has been able to live a good life with no admissions for relapse. F/U visits q 3mo with a psychiatrist is important as well as lab work.
1Patient Review
12/7/2016
Fluphenazine Decanoate for Schizophrenia
I was extremely disappointed with this product. Not only did the injection hurt, but I also got an infection and lost my arm as a result. Do not buy this!
1Patient Review
2/9/2021
Fluphenazine Decanoate for Mental Disorder with Loss of Normal Personality & Reality
I experienced sexual dysfunction while taking this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fluphenazine decanoate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is fluphenazine decanoate administered?

"Fluphenazine decanoate is a medication that is typically injected deep into the muscle in the buttock area. Most patients stay within the dosage range of 12.5 mg to 100 mg, given at intervals of two to five weeks."

Answered by AI

What are the side effects of fluphenazine?

"Possible side effects include drowsiness, lethargy, dizziness, nausea, loss of appetite, sweating, dry mouth, blurred vision, headache, and constipation. Let your doctor know if any of these effects are severe or don't go away."

Answered by AI

What is another name for fluphenazine decanoate?

"Fluphenazine is a drug used to treat symptoms of schizophrenia. It is available under different brand names, including Modecate, Modecate Concentrate, Moditen, Prolixin (discontinued brand), and RhoFluphenazine."

Answered by AI

What is fluphenazine decanoate used for?

"The medication Fluphenazine decanoate belongs to the family of antipsychotics, more specifically the phenothiazines. It is used to treat schizophrenia and is thought to work by reducing dopamine in certain areas of the brain."

Answered by AI

Clinical Trials for Fluphenazine Decanoate

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA
The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical CenterScott Irwin, MD
Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA
The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.
Waitlist Available
Has No Placebo
University of California San Diego
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL
This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.
Recruiting
Has No Placebo
Mayo Clinic in FloridaJuan C. Cardenas Rosales, MD
Have you considered Fluphenazine Decanoate clinical trials? We made a collection of clinical trials featuring Fluphenazine Decanoate, we think they might fit your search criteria.Go to Trials
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL
The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.
Waitlist Available
Has No Placebo
Virtual/ No Physical FacilityCandice S Rasa, LCSW
Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA
The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.
Phase 2
Recruiting
University of California, Los Angeles
Have you considered Fluphenazine Decanoate clinical trials? We made a collection of clinical trials featuring Fluphenazine Decanoate, we think they might fit your search criteria.Go to Trials
Image of St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Multimodal Intervention for Bipolar Disorder

18 - 35
All Sexes
Hamilton, Canada
People with bipolar disorder (BD) are at high risk of relapse following hospital discharge, partly due to a lack of BD-specific expertise and resources within community services required for comprehensive treatment. Although clinical guidelines recommend combining medication and psychosocial support, and research shows that early intervention is associated with improved outcomes, no structured care programs currently exist for individuals in the early stages of BD, contributing to chronic illness progression and preventable hospitalizations. This open-label pilot trial will assess the feasibility, acceptability, and preliminary effectiveness of a structured care pathway to support the transition from hospital to community care. The intervention includes group-based psychoeducation, individual peer support, and personalized support for community healthcare providers to improve illness insight, treatment adherence, and symptom management.
Waitlist Available
Has No Placebo
St. Joseph's Healthcare Hamilton
Image of Syracuse VA Medical Center, Syracuse, NY in Syracuse, United States.

Self-Help Intervention for Depression and PTSD

18+
All Sexes
Syracuse, NY
It is important to provide support and resources for the many post-9/11 Veterans with mental health symptoms and poor psychosocial functioning who do not engage in psychotherapy. One of the biggest reasons post-9/11 Veterans do not seek treatment is a preference to handle problems on their own. This study examines a self-help intervention that teaches Veterans healthy coping strategies they can use on their own and how to seek out recovery support services such as mental health treatment or whole-person care if they decide to do so in the future. This study will compare the impact of self-help and standard resources at improving mental health and resource utilization. Two hundred Veterans will complete 6 brief assessments across 40 weeks.
Waitlist Available
Has No Placebo
Syracuse VA Medical Center, Syracuse, NY (+1 Sites)Robyn L. Shepardson, PhD
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Brain Stimulation for Cannabis Craving in Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cue-induced craving and cognitive performance in individuals with schizophrenia and schizoaffective disorder, while targeted stimulation of the L DLPFC leads to these changes in healthy controls who use cannabis. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of cannabis use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at reducing craving and improving cognitive performance in individuals with schizophrenia and schizoaffective disorder. This is a study of the effect of 2 rTMS interventions on functional connectivity and craving in individuals with schizophrenia or schizoaffective disorder and healthy controls who use cannabis. Aim 1: Target Engagement: Determine if rTMS manipulates functional connectivity of each target (DMN, L DLPFC) (n=100). Aim 2: Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100). As an exploratory analysis, the factors that explain individual variance in rTMS-induced connectivity change will also be explored.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric Hospital
Have you considered Fluphenazine Decanoate clinical trials? We made a collection of clinical trials featuring Fluphenazine Decanoate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security